Amarin Making The Best Of Vascepa As Battle Continues With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech has been making lemonade of its fight with FDA for expanded use of its fish-oil drug Vascepa by upping its promotion of the current indication, but executives continue to sound pessimistic about winning over the agency.